SKB565 for Injection in Advanced Solid Tumors

Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Study ID
NCT07545265
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SKB565 — DRUG
    IV infusion on Day 1 and Day 15 of each cycle, every 4 weeks (Q4W), until radiographic disease progression (PD), intolerable toxicity, participant request for discontinuation, lost to follow-up, or death (whichever occurs first).

Study Details

This is a phase I/II clinical study to evaluate the safety and efficacy of SKB565 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.

Key Dates

First listed
Apr 22, 2026
Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Dec 31, 2028
Completion
May 31, 2029

Study Design

Enrollment
180 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SKB565 monotherapy
    SKB565 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle

Primary Outcome Measure

Number of subjects achieving Dose-limiting toxicity (DLT) [ Time Frame: Day 1 to Day 28 in Cycle 1 in the dose escalation part ]

Central Contacts

Related Studies